Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Duramed Research |
---|---|
Information provided by: | Duramed Research |
ClinicalTrials.gov Identifier: | NCT00196352 |
This study is being conducted to evaluate the safety of ethinyl an extended-regimen oral contraceptive, with ethinyl estradiol supplementation during the usual hormone-free week, for up to an additional three consecutive years.
Condition | Intervention | Phase |
---|---|---|
Contraception |
Drug: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Prospective, Multiple Site Study to Evaluate the Safety of an Extended Cycle Combination Oral Contraceptive, Seasonique, Which Utilizes Ethinyl Estradiol During the Pill-Free Interval. |
Enrollment: | 320 |
Study Start Date: | May 2003 |
Study Completion Date: | November 2006 |
Primary Completion Date: | November 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets
1 tablet daily
|
This study is being conducted to evaluate the safety of an extended-regimen oral contraceptive, with ethinyl estradiol supplementation during the usual hormone-free week, for up to an additional three consecutive years. This is an extension of the Seasonique Phase 3 clinical trial to evaluate long-term safety. Only patients enrolled in the earlier trial are eligible for participation.
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Duramed Investigational Site | |
Tucson, Arizona, United States, 85715 | |
United States, District of Columbia | |
Duramed Investigational Site | |
Washington, District of Columbia, United States, 20006 | |
United States, Nebraska | |
Duramed Investigational Site | |
Lincoln, Nebraska, United States, 68510 | |
United States, New York | |
Duramed Investigational Site | |
Rochester, New York, United States, 14609 | |
United States, North Carolina | |
Duramed Investigational Site | |
Winston-Salem, North Carolina, United States, 27103 | |
Duramed Investigational Site | |
Charlotte, North Carolina, United States, 28209 | |
United States, Ohio | |
Duramed Investigational Site | |
Columbus, Ohio, United States, 43213 | |
United States, Oklahoma | |
Duramed Investigational Site | |
Oklahoma City, Oklahoma, United States, 73112 | |
United States, Tennessee | |
Duramed Investigational Site | |
Nashville, Tennessee, United States, 37203 | |
United States, Virginia | |
Duramed Investigational Site | |
Norfolk, Virginia, United States, 23507 | |
Duramed Investigational Site | |
Arlington, Virginia, United States, 22203 |
Study Chair: | Duramed Protocol Chair | Duramed Research, Inc. |
Responsible Party: | Duramed Research, Inc. ( Duramed Protocol Chair ) |
Study ID Numbers: | PSE-304 |
Study First Received: | September 12, 2005 |
Last Updated: | February 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00196352 |
Health Authority: | United States: Food and Drug Administration |
oral contraceptives birth control ethinyl estradiol pregnancy prevention |
Levonorgestrel Estradiol 3-benzoate Estradiol valerate Ethinyl Estradiol |
Estradiol 17 beta-cypionate Polyestradiol phosphate Estradiol |
Estrogens Contraceptive Agents Therapeutic Uses Contraceptives, Oral Physiological Effects of Drugs Contraceptive Agents, Female |
Hormones, Hormone Substitutes, and Hormone Antagonists Contraceptives, Oral, Synthetic Reproductive Control Agents Hormones Pharmacologic Actions |